128 related articles for article (PubMed ID: 28266249)
1. What are the latest advancements in acute myeloid leukemia therapy?
Goodman A; Ball ED
Future Oncol; 2017 Apr; 13(10):867-871. PubMed ID: 28266249
[No Abstract] [Full Text] [Related]
2. [FLT3 inhibitors for acute myeloid leukemia].
Kiyoi H
Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
4. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
Miyamoto K; Minami Y
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
6. Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.
Prommersberger S; Jetani H; Danhof S; Monjezi R; Nerreter T; Beckmann J; Einsele H; Hudecek M
Curr Res Transl Med; 2018 May; 66(2):37-38. PubMed ID: 29655962
[No Abstract] [Full Text] [Related]
7. Midostaurin Gets FDA Nod for AML.
Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
[TBL] [Abstract][Full Text] [Related]
8. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
9. A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition.
Koshy AG; Daver NG; Fathi AT
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101220. PubMed ID: 33279176
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
11. [Application of novel tyrosine-kinase inhibitors for the treatment of leukemia and Ph-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2011 Jul; 52(7):460-8. PubMed ID: 21821977
[No Abstract] [Full Text] [Related]
12. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Mohan BP; How GF; Loh Y; Linn YC
Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
[No Abstract] [Full Text] [Related]
13. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
14. Identification of mast cells as a candidate significant target of immunotherapy for acute myeloid leukemia.
Jia M; Zhang H; Wang L; Zhao L; Fan S; Xi Y
Hematology; 2021 Dec; 26(1):284-294. PubMed ID: 33648435
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
16. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
[TBL] [Abstract][Full Text] [Related]
18. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
19. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]